

INTERCEPT® Blood System for Platelets Pathogen Reduction System

The INTERCEPT Blood System is comprised of disposable kits for platelets and a UVA Illuminator.



INTERCEPT Blood System for Platelets

Compatible with Amicus® apheresis platelet components suspended in PAS-3 or Trima® apheresis platelet components suspended in 100% plasma.

Sets are available in three configurations: Small Volume (SV), Large Volume (LV) and Dual Storage (DS).



INTERCEPT INT100 Illuminator

Compatible with all INTERCEPT processing sets for Platelets (SV, LV, DS).

INTERCEPT[®] Blood System for Platelets Pathogen Reduction System

Input and Processing Specifications



Platelets in PAS-3

	Small Volume Set (SV)	Large Volume Set (LV)	Dual Storage Set (DS)	
Product Code	INT2130B	INT2230B	INT2530B	
Platelet Source	Amicus Apheresis	Amicus Apheresis	Amicus Apheresis	
Suspension Medium	PAS-3 & Plasma (32-47%)	PAS-3 & Plasma (32-47%)	PAS-3 & Plasma (32-47%)	
Platelet Input Volume (mL)	255 - 325	300 - 390	300 - 390	375 - 420
Platelet Dose (x10¹¹)	2.9 - 5.0	3.0 - 6.0	3.0 - 6.0	4.0 - 8.0
Platelet Count (x10⁹/mL)	0.9 - 2.0	0.8 - 2.0	0.8 - 2.0	0.95 - 2.1
RBC (x10⁶/mL)	< 4	< 4	< 4	< 4
CAD Time (hours)	4 -16	6 -16	6 -16	6 -16
Integrated Storage Containers	1	1	1	1 or 2
Units per Carton	24 (Packaged as 4 foil pouches with 6 processing sets per pouch)			

Platelets must be treated with the INTERCEPT System within 24 hours after collection.



Platelets in 100% Plasma

	Small Volume Set (SV)	Large Volume Set (LV)	Dual Storage Set (DS)	
Product Code	INT2130B	INT2230B		INT2530B
Platelet Source	Trima Apheresis	Trima Apheresis		Trima Apheresis
Suspension Medium	100% Plasma	100% Plasma		100% Plasma
Platelet Input Volume (mL)	270 - 325	300 - 390	300 - 390	375 - 420
Platelet Dose (x10¹¹)	3.0 - 5.0	3.0 - 5.2	3.0 - 5.2	5.3 - 7.9
Platelet Count (x10⁹/mL)	0.9 - 2.0	0.8 - 1.7	0.8 - 1.7	1.3 - 2.1
RBC (x10⁶/mL)	< 4	< 4	< 4	< 4
CAD Time (hours)	12 - 24	12 - 24	12 - 24	12 - 24
Integrated Storage Containers	1	1	1	2
Units per Carton	24 (Packaged as 4 foil pouches with 6 processing sets per pouch)			

Platelets must be treated with the INTERCEPT System within 24 hours after collection.

INTERCEPT® INT100 Illuminator

Input and Processing Specifications



Illuminator should be used in environmental conditions that meet the following:

- Temperature 18-30°C
- Humidity < 80%

INT100 Specifications

Order Code	INT100-60
Power Supply	120 VAC / 60 Hz / 5 A max
Measurements	H=14.5" / W=45" / D=29"
Weight	152 lbs

The UVA Illuminator is stackable by two, for maximum space efficiency.

INTERCEPT treatment using products INT2130B, INT2230B, or INT2530B requires an INT 100 with software version 6 or newer.

CONTRAINDICATIONS

Only INTERCEPT Processing Sets for platelets are approved for use with the INTERCEPT Blood System. Use only the INTERCEPT INT100 Illuminator for UVA illumination of amotosalen-treated platelet components. No other source of UVA light may be used. Please refer to the Operator's Manual for the INT100 Illuminator. Discard any platelet components not exposed to the complete INT100 illumination process. Tubing components and container ports of the INTERCEPT Blood System contain polyvinyl chloride (PVC). Di(2-ethylhexyl)phthalate (DEHP) is known to be released from PVC medical devices, and increased leaching can occur with extended storage or increased surface area contact. Blood components will be in contact with PVC for a brief period of time (approx. 15 minutes) during processing. The risks associated with DEHP released into the blood components must be weighed against the benefits of therapeutic transfusion. Contraindicated for preparation of platelet components or plasma intended for patients with a history of hypersensitivity reaction to amotosalen or other psoralens.

WARNINGS AND PRECAUTIONS

PLATELETS : Pulmonary events: Acute Respiratory Distress Syndrome (ARDS). INTERCEPT processed platelets may cause the following adverse reaction: Acute Respiratory Distress Syndrome (ARDS). An increased incidence of ARDS was reported in a randomized trial for recipients of INTERCEPT processed platelets, 5/318 (1.6%), compared to recipients of conventional platelet components (0/327). Monitor patients for signs and symptoms of ARDS.

Rx Only. See package inserts for full prescribing information.



GLOBAL HEADQUARTERS | 1220 Concord Avenue | Concord, CA US 94520 | 855.835.3523

www.cerus.com | www.intercept-usa.com

Rx only. See package insert for full prescribing information.

Amicus is a registered trademark of Fenwal Inc. Trima is a registered trademark of Terumo BCT, Inc.